Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease

Aguillon, David ; Langella, Stephanie ; Chen, Yinghua ; Sanchez, Justin S. ; Su, Yi ; Vila-Castelar, Clara ; Vasquez, Daniel ; Zetterberg, Henrik ; Hansson, Oskar LU orcid and Dage, Jeffrey L. , et al. (2023) In Alzheimer's and Dementia 19(6). p.2585-2594
Abstract

Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels... (More)

Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
autosomal dominant Alzheimer's disease, blood biomarkers, dementia, presenilin-1, tau pathology
in
Alzheimer's and Dementia
volume
19
issue
6
pages
2585 - 2594
publisher
Wiley
external identifiers
  • pmid:36571821
  • scopus:85145230114
ISSN
1552-5260
DOI
10.1002/alz.12906
language
English
LU publication?
yes
id
4679747f-e1fb-451b-be0d-38c9758e3adf
date added to LUP
2023-02-10 15:38:09
date last changed
2024-04-18 00:29:57
@article{4679747f-e1fb-451b-be0d-38c9758e3adf,
  abstract     = {{<p>Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.</p>}},
  author       = {{Aguillon, David and Langella, Stephanie and Chen, Yinghua and Sanchez, Justin S. and Su, Yi and Vila-Castelar, Clara and Vasquez, Daniel and Zetterberg, Henrik and Hansson, Oskar and Dage, Jeffrey L. and Janelidze, Shorena and Chen, Kewei and Fox-Fuller, Joshua T. and Aduen, Paula and Martinez, Jairo E. and Garcia, Gloria and Baena, Ana and Guzman, Claudia and Johnson, Keith A. and Sperling, Reisa A. and Blennow, Kaj and Reiman, Eric M. and Lopera, Francisco and Quiroz, Yakeel T.}},
  issn         = {{1552-5260}},
  keywords     = {{autosomal dominant Alzheimer's disease; blood biomarkers; dementia; presenilin-1; tau pathology}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{2585--2594}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.12906}},
  doi          = {{10.1002/alz.12906}},
  volume       = {{19}},
  year         = {{2023}},
}